Arthur J. Smerling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Arthur J. Smerling has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Adnan M. Bakar
Albany Medical Center
1 shared publication - Aimee Jennings
Division of Critical Care, Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington
1 shared publication C. A. Lawson
Department of Anesthesiology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
1 shared publication- Charles Schleien
Cohen Children’s Medical Center of NY
1 shared publication - Christine M. Riley
Children’s National Health System
1 shared publication - Christopher W. Mastropietro
Division of Critical Care, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, Ind
1 shared publication
Latest Publications
- 6 September 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 115 (1) , 144-150
Contemporary Multicenter Outcomes for Truncus Arteriosus With Interrupted Aortic Arch
- 6 September 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 115 (1) , 144-150
Contemporary Multicenter Outcomes for Truncus Arteriosus With Interrupted Aortic Arch
- 1 February 2013
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 25 (1) , 62-65
Pentobarbital withdrawal and treatment in an infant in the pediatric cardiac intensive care unit
- 1 February 2013
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 25 (1) , 62-65
Pentobarbital withdrawal and treatment in an infant in the pediatric cardiac intensive care unit
- 1 December 2004
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 32 (Supplement) , A48
EARLY SERUM TROPONIN PREDICTS LENGTH OF STAY IN POST-OPERATIVE TETRALOGY OF FALLOT PATIENTS
- 1 December 2004
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 32 (Supplement) , A48
EARLY SERUM TROPONIN PREDICTS LENGTH OF STAY IN POST-OPERATIVE TETRALOGY OF FALLOT PATIENTS
- 1 May 1995
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 268 (5) , H2056-H2062
Selective reduction of PVR by inhalation of a cGMP analogue in a porcine model of pulmonary hypertension
Selective reduction of pulmonary vascular resistance (PVR) remains a therapeutic goal for the treatment of pulmonary hypertension, but current therapeutic options remain limited. Although the gas nitric oxide (NO) selectively dilates the pulmonary vascular bed, it requires special equipment for administration, has a short biologic half-life, and is potentially toxic. We hypothesized that stimulation of the NO pathway at the level of its second messenger, guanosine 3',5'-cyclic monophosphate (cGMP), by targeted pulmonary delivery of a membrane-permeable nonhydrolyzable cGMP analogue would cause selective pulmonary vasodilation. Pulmonary hypertension was induced in 21 pigs by the intravenous infusion of a thromboxane A2 analogue (9,11-dideoxy-9 alpha,11 alpha-epoxymethanoprostaglandin F2 alpha). Inhaled 8-bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP) lowered PVR in a time- and dose-dependent manner, with maximal effect achieved after 20 min. Compared with physiological saline control, 8-BrcGMP inhalation (3.0 micrograms/kg) lowered PVR by 25 +/- 3% (P < 0.01), whereas there was no significant decline in systemic vascular resistance (4 +/- 6%); mean pulmonary arterial pressure declined 13 +/- 3% (P < 0.01), whereas there was little change in mean arterial pressure; cardiac output increased 10 +/- 4% (P < 0.05). PVR did not decrease after inhalation of noncyclic 8-bromoguanosine 5'-monophosphate, indicating that stimulation of the NO-cGMP pathway beyond the level of NO results in pulmonary vasodilation independent of stimulation of purinergic receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
- 1 May 1995
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 268 (5) , H2056-H2062
Selective reduction of PVR by inhalation of a cGMP analogue in a porcine model of pulmonary hypertension
Selective reduction of pulmonary vascular resistance (PVR) remains a therapeutic goal for the treatment of pulmonary hypertension, but current therapeutic options remain limited. Although the gas nitric oxide (NO) selectively dilates the pulmonary vascular bed, it requires special equipment for administration, has a short biologic half-life, and is potentially toxic. We hypothesized that stimulation of the NO pathway at the level of its second messenger, guanosine 3',5'-cyclic monophosphate (cGMP), by targeted pulmonary delivery of a membrane-permeable nonhydrolyzable cGMP analogue would cause selective pulmonary vasodilation. Pulmonary hypertension was induced in 21 pigs by the intravenous infusion of a thromboxane A2 analogue (9,11-dideoxy-9 alpha,11 alpha-epoxymethanoprostaglandin F2 alpha). Inhaled 8-bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP) lowered PVR in a time- and dose-dependent manner, with maximal effect achieved after 20 min. Compared with physiological saline control, 8-BrcGMP inhalation (3.0 micrograms/kg) lowered PVR by 25 +/- 3% (P < 0.01), whereas there was no significant decline in systemic vascular resistance (4 +/- 6%); mean pulmonary arterial pressure declined 13 +/- 3% (P < 0.01), whereas there was little change in mean arterial pressure; cardiac output increased 10 +/- 4% (P < 0.05). PVR did not decrease after inhalation of noncyclic 8-bromoguanosine 5'-monophosphate, indicating that stimulation of the NO-cGMP pathway beyond the level of NO results in pulmonary vasodilation independent of stimulation of purinergic receptors.(ABSTRACT TRUNCATED AT 250 WORDS)